Symbols

VCYT

Veracyte·NASDAQ

--(--)

VCYT fundamentals

VCYT Q4 2025 Earnings

Veracyte (VCYT) released its earnings on Feb 25, 2026: revenue was 140.64M (YoY +18.55%), beat estimates; EPS was 0.53 (YoY +783.33%), beat estimates.

Revenue / YoY

140.64M

+18.55%

EPS / YoY

0.53

+783.33%

Report date

Feb 25, 2026

VCYT Earnings Call Summary for Q4,2025

Revenue milestone: Q4 2025 revenue up 19% YoY to $141 million, full-year at $517 million (16% growth).
Product launches: TrueMRD for MIBC and Prosigna LDT in 2026, targeting 70% of MIBC patients and 225,000 breast cancer patients.
Profitability: 2025 EBITDA margin 27.6%, guiding to 25% in 2026 with $10 million+ investment in new products.
Competitive edge: Decipher at 33% market share, no material competitor impact; Afirma no-result rate down 2% QoQ.
Cash generation: $412.9 million cash on hand, up $120 million YoY.

Earnings

EPS

Revenue

Revenue & Expenses

VCYT has released its 2025 Q4 earnings report, with revenue of 140.64M, reflecting a YoY change of 18.55%, and net profit of 41.15M, showing a YoY change of 704.79%. The Sankey diagram below clearly presents VCYT's revenue sources and cost distribution.

Key Indicators

Veracyte (VCYT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Veracyte (VCYT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Veracyte (VCYT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Veracyte (VCYT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown